These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36691808)

  • 1. Managing an extension of screening intervals: Avoiding boom and bust in health care workloads.
    Pesola F; Rebolj M; Sasieni P
    Int J Cancer; 2023 May; 152(10):2061-2068. PubMed ID: 36691808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
    Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
    BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen.
    Silver MI; Schiffman M; Fetterman B; Poitras NE; Gage JC; Wentzensen N; Lorey T; Kinney WK; Castle PE
    Cancer; 2016 Dec; 122(23):3682-3686. PubMed ID: 27657992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
    Gilham C; Sargent A; Kitchener HC; Peto J
    Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of the effect of introducing a restrictive cervical screening policy on laboratory workload and cervical cancer detection rates.
    Channer JL; Mackenzie EF
    Cytopathology; 1990; 1(1):13-7. PubMed ID: 2130995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
    Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
    Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-grade cervical abnormalities and screening intervals in New South Wales, Australia.
    Schindeler S; Morrell S; Zuo Y; Baker D
    J Med Screen; 2008; 15(1):36-43. PubMed ID: 18416954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extension of cervical screening intervals with primary human papillomavirus testing: observational study of English screening pilot data.
    Rebolj M; Cuschieri K; Mathews CS; Pesola F; Denton K; Kitchener H;
    BMJ; 2022 May; 377():e068776. PubMed ID: 35640960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use.
    Smith MA; Gertig D; Hall M; Simms K; Lew JB; Malloy M; Saville M; Canfell K
    BMC Health Serv Res; 2016 Apr; 16():147. PubMed ID: 27112193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testing key messages about extending cervical screening intervals.
    A V Marlow L; Nemec M; Barnes J; Waller J
    Patient Educ Couns; 2022 Aug; 105(8):2757-2762. PubMed ID: 35440375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated, HPV-negative women: a modelling study.
    Malagón T; Kulasingam S; Mayrand MH; Ogilvie G; Smith L; Bouchard C; Gotlieb W; Franco EL
    Lancet Oncol; 2018 Dec; 19(12):1569-1578. PubMed ID: 30392810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An examination of the role of opportunistic smear taking in the NHS cervical screening programme using data from the CSEU cervical screening cohort study.
    Blanks RG; Moss SM; Coleman DA; Swerdlow AJ
    BJOG; 2007 Nov; 114(11):1408-13. PubMed ID: 17803716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of nonscreening smears on screening smear results: a statistical analysis with its implications for the NHS cervical screening programme.
    Rice S; Slater DN; Hewer EM
    Cytopathology; 2000 Jun; 11(3):158-65. PubMed ID: 10877275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Health technology assessment report: Computer-assisted Pap test for cervical cancer screening].
    Della Palma P; Moresco L; Giorgi Rossi P
    Epidemiol Prev; 2012; 36(5 Suppl 3):e1-43. PubMed ID: 23139174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring and evaluation of a model demonstration project for the control of cervical cancer in Nakhon Phanom province, Thailand.
    Deerasamee S; Srivatanakul P; Sriplung H; Nilvachararung S; Tansuwan U; Pitakpraiwan P; Kaewkungwal J; Singhasivanon P; Nimnakorn P; Sankaranarayanan R
    Asian Pac J Cancer Prev; 2007; 8(4):547-56. PubMed ID: 18260727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 3-year interval is too short for re-screening women testing negative for human papillomavirus: a population-based cohort study.
    Zorzi M; Frayle H; Rizzi M; Fedato C; Rugge M; Penon MG; Bertazzo A; Callegaro S; Campagnolo M; Ortu F; Del Mistro A;
    BJOG; 2017 Sep; 124(10):1585-1593. PubMed ID: 28120382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Report from the CDC. Pap test intervals used by physicians serving low-income women through the National Breast and Cervical Cancer Early Detection Program.
    Cooper CP; Saraiya M; McLean TA; Hannan J; Liesmann JM; Rose SW; Lawson HW
    J Womens Health (Larchmt); 2005 Oct; 14(8):670-8. PubMed ID: 16232098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uptake of HPV testing and extended cervical cancer screening intervals following cytology alone and Pap/HPV cotesting in women aged 30-65 years.
    Silver MI; Rositch AF; Phelan-Emrick DF; Gravitt PE
    Cancer Causes Control; 2018 Jan; 29(1):43-50. PubMed ID: 29124542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPV testing in Polish population-based cervical cancer screening programme (HIPPO project)-study protocol of a randomised healthcare policy trial.
    Glinska P; Komerska K; Janik B; Olkowicz J; Jedrzejewska I; Macios A; Wieszczy P; Kaminski MF; Arbyn M; Nowakowski A
    BMC Cancer; 2023 Nov; 23(1):1118. PubMed ID: 37978452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.